N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide
• 英文别名: 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-methylsulfonylurea；1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-methylsulfonylurea
• 化学式: C₁₄H₁₈N₂O₃S
• 分子量: 294.375
• InChiKey: QZHOEGOLWOEMNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1,2,3,5,6,7-六氢-S-引达省-4-胺 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 1.67h， 生成 N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)methanesulfonamide
  参考文献：
  名称：

  [EN] CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
  [FR] COMPOSÉS CHIMIQUES COMME INHIBITEURS DE L'ACTIVITÉ INTERLEUKINE-1

  摘要：

  本公开涉及新型磺酰脲和磺酰硫脲化合物以及相关化合物，以及它们在治疗对细胞因子如IL-1β和IL-18的调节敏感的疾病或状况中的应用，调节NLRP3或抑制NLRP3或相关炎症过程组分的激活。

  公开号：

  WO2018136890A1

文献信息

• CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
  申请人：Genentech, Inc.

  公开号：EP3851434A1

  公开（公告）日：2021-07-21

  The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

  本公开涉及新型磺酰脲类和磺酰硫脲类化合物及相关化合物，以及它们在治疗对细胞因子如IL-1β和IL-18的调节、NLRP3的调节或抑制NLRP3或炎症过程中相关成分的活化有反应的疾病或病症中的用途。
• Chemical compounds as inhibitors of interleukin-1 activity
  申请人：Genentech, Inc.

  公开号：US11040985B2

  公开（公告）日：2021-06-22

  The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

  本公开涉及新型磺酰脲类和磺酰硫脲类化合物及相关化合物，以及它们在治疗对细胞因子如IL-1β和IL-18的调节、NLRP3的调节或抑制NLRP3或炎症过程中相关成分的活化有反应的疾病或病症中的用途。
• NOVEL SULFONEUREA COMPOUNDS
  申请人：Inflazome Limited

  公开号：US20210163412A1

  公开（公告）日：2021-06-03

  The present invention relates to compounds of formula (I): wherein A, B, L, X, Y, R 1 , R 2 and R 4 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP 3 .
• [EN] NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE SULFONAMIDE CARBOXAMIDE
  申请人：INFLAZOME LTD

  公开号：WO2019034697A1

  公开（公告）日：2019-02-21

  The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
• [EN] NOVEL SULFONEUREA COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE SULFONYLURÉE
  申请人：INFLAZOME LTD

  公开号：WO2020035465A1

  公开（公告）日：2020-02-20

  The present invention relates to compounds of formula (I): wherein A, B, L, X, Y, R1, R2 and R4 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.